The CEO stated that multiple macroeconomic factors continued to challenge the industry in our region and impacted our revenue. “We continue to adapt our strategies to navigate this dynamic landscape and protect our profitability, and we see positive trends materializing in the fourth quarter of 2023 that we expect will lead to improved results compared to the fourth quarter of the year. ”
During the reported period, the company announced the agreement with BDR Pharmaceuticals for 27 oncology molecules for Latin America, including 20 TKIs (Tyrosine Kinase Inhibitors). “Under the agreement, Procaps is responsible for registration, branding, marketing and merchandising throughout Latin America. “We are very excited to expand our oncology portfolio in the region and add more partner companies and potentially expand cancer treatment options with several new molecules to better serve more patients and physicians,” said Minski.
Procaps is supporting growing demand in the United States with its advanced gummy technologies for the global nutraceutical industry, and capacity expansion in this country continues as planned. the construction of the new rubber factory in La Florida.
“We expect operations to commence in the first quarter of 2024 with sales to occur later in the quarter. We also mainly research new products in the United States powerful connections, to take advantage of the facilities of West Palm Beachwhich have a production capacity of approximately 1,800 billion soft gelatin capsules per year for our business unit,” emphasizes Rubén Minski.
Source: El heraldo
Roy Brown is a renowned economist and author at The Nation View. He has a deep understanding of the global economy and its intricacies. He writes about a wide range of economic topics, including monetary policy, fiscal policy, international trade, and labor markets.
